Latent membrane protein 1, tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF-2, TRAF-3, and nuclear factor kappa B expression in posttransplantation lymphoproliferative disorders

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 10, 2003, Pages 1335-1339

  Ramalingam, Preetha ^a   Chu, Wei Sing ^b   Tubbs, Raymond ^a   Rybicki, Lisa ^a   Pettay, James ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHILD; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOGENESIS; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; VIRUS INFECTION;

BONE MARROW TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOPROLIFERATIVE DISORDERS; NF-KAPPA B; ORGAN TRANSPLANTATION; PROTEINS; RNA, VIRAL; TNF RECEPTOR-ASSOCIATED FACTOR 1; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; VIRAL MATRIX PROTEINS;

EID: 0141995532     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173-192.
2. Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323:1767-1769.
3. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res. 1981;41:4262-4279.
4. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood. 1988;72:349-352.
5. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552-565.
6. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338:1413-1421.
7. Izumi KM, Cahir McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J Virol. 1999;73:9908-9916.
8. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90:9150-9154.
9. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol. 1997;71:4649-4656.
10. Devergne O, Cahir McFarland ED, et al. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 1998;72:7900-7908.
11. Kaye KM, Izumi KM, Mosialos G, Kieff E. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol. 1995;69:675-683.
12. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1997;94:1447-1452.
13. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A. 1997;94:12592-12597.
14. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol. 1996;16:7098-7108.
15. Izban KF, Ergin M, Martinez RL, Alkan S. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol. 2000;13:1324-1331.
16. Krajewski S, Zapata JM, Krajewska M, et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol. 1997;159:5841-5852.
17. Murray PG, Swinnen LI, Flavell JR, et al. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. Hum Pathol. 2001;32:963-969.
18. Zapata JM, Krajewska M, Kralewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000;165:5084-5096.
19. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.
20. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol. 2002;15:647-656.
21. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
22. Izban KF, Ergin M, Qin JZ, et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol. 2000;31:1482-1490.
23. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappaB (NF-kappaB) in multiple myeloma: downregulation of NF-kappaB induces apoptosis. Br J Haematol. 2001;115:279-286.
24. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem. 2002;277:3863-3869.
25. Hellerbrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells. Am J Physiol. 1998;275:G269-G278.
26. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol. 2001;14:297-310.
27. Migliazza A, Lombardi L, Rocchi M, et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood. 1994;84:3850-3860.
28. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood. 1999;93:617-623.
29. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood. 1996;87:706-711.
30. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243-1252.
31. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn. 2001;3:1-10.
32. Smir BN, Hauke RJ, Bierman PI, et al. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest. 1996;75:575-588.